Lupin Ltd: Can the Comeback Kid of Pharma Conquer Global Markets Again?
1. At a Glance
Once battered by regulatory setbacks and margin crush, Lupin is rising from the ashes like a steroid-pumped phoenix. With margins back to double digits and US approvals rolling in, the stock’s got more bounce than an antidepressant ad.
2. Introduction with Hook
Imagine you were once the Rajinikanth of Indian pharma exports—unstoppable, stylish, and everywhere. Then came USFDA slaps, plunging margins, and shareholder heartbreak. That’s Lupin. But now? With FY25 profits up 71% and margins rebounding to 23%, Lupin’s comeback story is giving Rocky Balboa vibes.
Key Stat #1: Net Profit FY25: ₹3,306 Cr vs ₹1,936 Cr in FY24
Key Stat #2: OPM surge from 1% in FY22 to 23% in FY25
3. Business Model (WTF Do They Even Do?)
Lupin is the 9-to-9 workhorse of the pharma world, grinding out:
Branded generics across India and the US (its largest market)
APIs and complex generics in anti-TB, cardiovascular, and CNS
Biotech & inhalation products for chronic disease segments
Operates in 100+ countries, including the juicy but competitive US generics space
Owns 15+ manufacturing facilities, most USFDA-approved (with the occasional warning letter for spice)
They make pills. They make APIs. They make money. Occasionally, they make investors nervous.
